Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics

Zacks
Apri Zacks
Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics

The upcoming report from McKesson (MCK) is expected to reveal quarterly earnings of $10.69 per share, indicating an increase of 8.4% compared to the year-ago period. Analysts forecast revenues of $110.11 billion, representing an increase of 6.8% year over year.

Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.

Based on the collective assessment of analysts, 'Revenue- Prescription Technology Solutions' should arrive at $1.46 billion. The estimate indicates a change of +6% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenue- Medical-Surgical Solutions' will likely reach $3.04 billion. The estimate points to a change of +3.3% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Adjusted Operating Profit- Medical-Surgical Solutions' of $261.24 million. The estimate compares to the year-ago value of $249.00 million.

Analysts predict that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $295.09 million. Compared to the current estimate, the company reported $261.00 million in the same quarter of the previous year.

View all Key Company Metrics for McKesson here>>>

McKesson shares have witnessed a change of +9.1% in the past month, in contrast to the Zacks S&P 500 composite's +0.7% move. With a Zacks Rank #3 (Hold), MCK is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
McKesson Corporation (MCK): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research